Literature DB >> 1965077

Safety and immunogenicity of an inactivated hepatitis A candidate vaccine in healthy adult volunteers.

G Wiedermann1, F Ambrosch, H Kollaritsch, H Hofmann, C Kunz, E D'Hondt, A Delem, F E André, A Safary, J Stéphenne.   

Abstract

The reactogenicity and immunogenicity of a formaldehyde-inactivated hepatitis A vaccine have been investigated. Three different dose levels of vaccine (180, 360 and 720 ELISA units) were administered to healthy volunteers according to a 0, 1, 2 and 12 month schedule. The vaccine was safe and well tolerated. Reactions observed following vaccination were essentially mild and were not dependent upon the quantity of antigen administered. All subjects had measurable titres of anti-HAV antibodies after the full vaccination course; the immune response to the vaccine was dose-related. Antibody titres in vaccinees at month 13 were between 60- and 190-fold higher than those observed in a group of subjects given anti-HAV immunoglobulin.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1965077     DOI: 10.1016/0264-410x(90)90013-c

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  12 in total

1.  Hepatitis A.

Authors:  A J Tilzey; J E Banatvala
Journal:  BMJ       Date:  1991-06-29

2.  Antigenic and immunogenic properties of recombinant hepatitis A virus 14S and 70S subviral particles.

Authors:  J T Stapleton; V Raina; P L Winokur; K Walters; D Klinzman; E Rosen; J H McLinden
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

Review 3.  Clinical development of a new inactivated hepatitis A vaccine.

Authors:  E Vidor; B Fritzell; S Plotkin
Journal:  Infection       Date:  1996 Nov-Dec       Impact factor: 3.553

4.  Cost effectiveness of hepatitis A prevention in France.

Authors:  C A Severo; F Fagnani; A Lafuma
Journal:  Pharmacoeconomics       Date:  1995-07       Impact factor: 4.981

5.  Attenuated hepatitis A virus: genetic determinants of adaptation to growth in MRC-5 cells.

Authors:  A W Funkhouser; R H Purcell; E D'Hondt; S U Emerson
Journal:  J Virol       Date:  1994-01       Impact factor: 5.103

6.  Effect of rituximab on human in vivo antibody immune responses.

Authors:  Mark D Pescovitz; Troy R Torgerson; Hans D Ochs; Elizabeth Ocheltree; Paula McGee; Heidi Krause-Steinrauf; John M Lachin; Jennifer Canniff; Carla Greenbaum; Kevan C Herold; Jay S Skyler; Adriana Weinberg
Journal:  J Allergy Clin Immunol       Date:  2011-09-09       Impact factor: 10.793

7.  Hepatitis A in Western Austria--the epidemiological situation before the introduction of active immunisation.

Authors:  W M Prodinger; C Larcher; B M Sölder; D Geissler; M P Dierich
Journal:  Infection       Date:  1994 Jan-Feb       Impact factor: 3.553

8.  Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A.

Authors:  R Glück; R Mischler; S Brantschen; M Just; B Althaus; S J Cryz
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

9.  The hepatitis A virus polyprotein expressed by a recombinant vaccinia virus undergoes proteolytic processing and assembly into viruslike particles.

Authors:  P L Winokur; J H McLinden; J T Stapleton
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

10.  Clinical trial with inactivated hepatitis A vaccine and recommendations for its use.

Authors:  A J Tilzey; S J Palmer; S Barrow; K R Perry; H Tyrrell; A Safary; J E Banatvala
Journal:  BMJ       Date:  1992-05-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.